ReviewDrugs2010
Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens.Medicine · 2015Pooled it
- Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer.Molecular therapy. Oncology · 2024Article
- Exploring the impact of therapeutic advances in HIV-related mortality in the United States.IJID regions · 2024Article
- Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).Viruses · 2023Review
- Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects.Frontiers in chemistry · 2022Review
- Karacoline, identified by network pharmacology, reduces degradation of the extracellular matrix in intervertebral disc degeneration via the NF-κB signaling pathway.Journal of pharmaceutical analysis · 2020Article
- Mass Spectrometry Imaging Demonstrates the Regional Brain Distribution Patterns of Three First-Line Antiretroviral Drugs.ACS omega · 2019Article
- Pattern of and reasons for antiretroviral therapy regimen change among adult HIV/AIDS patients at regional hospital in Eastern Ethiopia: A 10-year retrospective study.SAGE open medicine · 2019Article
- Appropriateness of Cotrimoxazole Prophylactic Therapy Among HIV/AIDS Patients in Public Hospitals in Eastern Ethiopia: A Retrospective Evaluation of Clinical Practice.Frontiers in pharmacology · 2018Article
- Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.PloS one · 2016Observational
- Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications.Infectious diseases and therapy · 2015Article
- Single Tablet Regimen Usage and Efficacy in the Treatment of HIV Infection in Australia.AIDS research and treatment · 2015Article
- Single-Tablet Regimens in HIV Therapy.Infectious diseases and therapy · 2014Article
- Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Pediatric health, medicine and therapeutics · 2014Article
- The impact of neurobehavioral features on medication adherence in HIV: evidence from longitudinal models.AIDS care · 2014Article
- Article
- Review
- In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.Drug metabolism and pharmacokinetics · 2013Article
- Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.Journal of acquired immune deficiency syndromes (1999) · 2012Article
- Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes.Molecules (Basel, Switzerland) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-nucleoside reverse transcriptase inhibitor, efavirenz, and the two nucleoside reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) are now available as a single-tablet regimen (efavirenz/emtricitabine/tenofovir DF 600 mg/200 mg/300 mg; Atripla®). The efavirenz/emtricitabine/tenofovir DF single-tablet regimen is the first once-daily, single-tablet, triple antiretroviral therapy (ART) formulation available for the treatment of HIV infection and, in the EU, is indicated for use in adults infected with HIV-1 who have been virologically suppressed for >3 months on their current ART regimen. In treatment-experienced adults with HIV-1 infection already virologically suppressed with ART, switching to once-daily triple combination therapy with efavirenz, emtricitabine and tenofovir DF (including the single-tablet regimen) is effective in maintaining virological suppression and is generally well tolerated, according to several randomized, open-label or noncomparative multicentre trials and an open-label extension study of up to 96 weeks' duration. Moreover, additional data from some of these studies indicate that adherence to treatment was maintained or improved after switching to the once-daily triple combination, with patients generally preferring the efavirenz/emtricitabine/tenofovir DF single-tablet regimen over their previous more complex regimen and (in one of two trials) finding it easier to follow. Thus, the efavirenz/emtricitabine/tenofovir DF single-tablet regimen provides a convenient once-daily regimen for use in treatment-experienced adults that may confer an advantage over more complex or frequently administered regimens for which adherence to treatment is an issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.